Product Information | RaQualia Pharma Inc.

Home
Product Information

: RaQualia's broad product portfolio ranges from development candidate compounds to products that are available in overseas markets. All of these products respond to both Japan's domestic medical needs and global opportunities. We analyze development candidate compounds forhighly-marketable, global target indications, responding to areas of high medical needs to build a sustainable product pipeline.

(March 15, 2011)

Japan Product Portfolio

(October 20, 2011)

Global Product Portfolio

Corporate Information: CEO Message; Company Overview; Vision, Management Principle and Culture; Corporate Governance; Business Model; Origins of Our Corporate Name and Logo; Facilities; Access; Press Release
Research & Development: Collaboration; Partnering in Research; What are Research Tools?; Research Tool Licensing

Product Information: Anidulafungin; Ziprasidone; Dalbavancin; EP₄ Antagonist; Cyclooxygenase-2 (COX-2) Inhibitor; Ghrelin Receptor Agonist; 5-HT₄ Partial Agonist; Acid Pump Antagonist; 5-HT_2B Antagonist; CB₂ Agonist; Motilin Receptor Agonist; Licensing

Shareholder and Investor Information

To our Shareholders and Investors

Vision, Management Principle and Culture

Corporate Governance

Outline of Securities Matters

IR Related News

Understanding RaQualia Pharma! RaQualia FAQ: RaQualia's History; What does RaQualia Pharma do?; How Does RaQualia Earn Revenues?; What About Dividends?; What are RaQualia's strengths?; What Does the Future Hold for RaQualia Pharma?

Corporate Introduction Video
Contributions to Society: Corporate Contributions; Contributions to the Community; Press Release; Topics